Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 22, 2018

Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report (N1.002)

Andrew Zimmerman, Eileen Diggins, Susan Connors, Kanwaljit Singh
First published April 9, 2018,
Andrew Zimmerman
1UMass Memorial Medical Center Worcester MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eileen Diggins
2Pediatrics, UMass Medical School Worcester MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Connors
2Pediatrics, UMass Medical School Worcester MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kanwaljit Singh
2Pediatrics, UMass Medical School Worcester MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD) – A Progress Report (N1.002)
Andrew Zimmerman, Eileen Diggins, Susan Connors, Kanwaljit Singh
Neurology Apr 2018, 90 (15 Supplement) N1.002;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Study the safety, clinical effects and mechanisms of action of sulforaphane in ASD.

Background: Direct treatment of underlying mechanisms in ASD is limited. The “fever effect” in ASD, in which febrile illness temporarily ameliorates disordered behavior, may offer a clinical clue. Fever stimulates heat shock proteins (HSP) and cellular stress responses, leading to improved synaptic function and long-range connectivity. Expression of gene transcription by NFE2L2 (Nrf2), which is reduced in ASD, also increases during fever. Sulforaphane (SF), an isothiocyanate obtained from broccoli sprouts, induces HSP and Nrf2 as well as “cell-protective” responses that may benefit ASD through common cellular mechanisms underlying heterogeneous phenotypes.

Design/Methods: This is a randomized, double-blind, placebo-controlled phase-2 clinical trial to test the safety and efficacy of oral SF in 50 children (age 3–12 years) with ASD. Treatment period is 30 weeks, with study-visits at screening, 7, 15, 22, 30 and 36 weeks. The first 15 weeks are double-blind, 1:1 placebo-controlled, and the second 15 weeks are open-label with all participants receiving SF. Ohio Autism Clinical Global Impressions Scale – Severity and Improvement (OACIS-S and I), Aberrant Behavior Checklist (ABC) and Social Responsiveness Scale (SRS) are administered at each study visit. Samples are collected for clinical and research lab studies at each visit.

Results: To date, we have enrolled 46 participants in the study; 24 participants have completed the trial, and 22 are actively enrolled. A preliminary analysis of the OACIS-I showed that 26% participants were much/very much improved at 7 weeks, 38% at 15 weeks, 64% at 22 weeks, and 64% at 30 weeks. Most common adverse events so far are insomnia (17%), flatulence (15%) and constipation (13%). Enrollment is expected to be complete in November, 2017, and full results after July, 2018.

Conclusions: Our preliminary results show that sulforaphane appears to be safe and effective in children with ASD.

Study Supported by: United States Department of Defense

Disclosure: Dr. Zimmerman has nothing to disclose. Dr. Diggins has nothing to disclose. Dr. Connors has nothing to disclose. Dr. Singh has nothing to disclose.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise